Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Del Williams
Options to address the risk of combustible dust explosions for NFPA 61 compliance
Doug Folsom
Unpatched vulnerabilities will become increasingly susceptible to cyberattacks
Del Williams
Mitigate risk, prevent safety issues by utilizing closed conveyor systems designed with sanitation in mind
Dirk Dusharme @ Quality Digest
Companies say they plan to pull some or all of their devices
Dirk Dusharme @ Quality Digest
First step, migrate your QMS to a cloud-based electronic quality management system

More Features

FDA Compliance News
Company’s first funding round will be used to accelerate product development for its QMS and MES SaaS offerings
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community
Good quality is adding an average of 11 percent to organizations’ revenue growth

More News

Thomas Abrams

FDA Compliance

FDA Sponsors e-Learning for Evaluating Drug Promotion

Bad Ad program’s course and case studies help identify harmful and misleading ads

Published: Wednesday, October 30, 2013 - 10:38

You probably have seen many consumer advertisements for prescriptions drugs—on TV, in magazines, or online. Although those ads are expensive, did you know that in 2010, pharmaceutical companies actually spent more money advertising to healthcare professionals than they spent advertising to consumers?

Here at the FDA, our Office of Prescription Drug Promotion monitors the information that pharmaceutical companies give to healthcare professionals about prescription drugs. We want to make sure the information your doctor or prescriber receives is truthful and not misleading because they may use it when deciding what medicines to prescribe to you, their patient.

We have just launched via our learning portal, Medscape, an e-learning course and case studies as part of our Bad Ad program, which is designed to raise awareness among healthcare professionals and students in various health programs about drug ads and promotional materials that might be untruthful or misleading, and how to report them to the FDA. The course offers continuing medical education credit for physicians and continuing education credit for other healthcare professionals. Although the target audience for the course is healthcare professionals, anyone can take the course.

In addition, because students are actively engaged in forming clinical practice habits that may last throughout their careers, reaching them now with Bad Ad information could have a strong impact on how they view prescription drug promotion. To help them become discerning readers of drug promotional information, we in the Office of Prescription Drug Promotion have developed several case studies based on FDA Warning and Untitled letters issued to drug companies. The case studies, which represent common problems, can be downloaded from the Bad Ad website.

We encourage medical, pharmacy, nursing, and other healthcare-related schools to incorporate these cases into their coursework. The cases cover a range of promotional materials including a website, journal ad, and TV ad, and touch upon numerous promotional practices that don’t comply with our regulations. Through the case studies, students will have an opportunity to evaluate and discuss these real-life examples of misleading drug promotion.

Our new e-learning courses and cases studies are the latest of many ways the FDA works to help ensure that your healthcare professionals have truthful and accurate information when making decisions that affect your health and safety.


About The Author

Thomas Abrams’s picture

Thomas Abrams

Thomas Abrams is the director of FDA’s Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research.